A Phase I Study to Evaluate the Safety, Tolerability, and Effect of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), on Markers of HIV Persistence in ART-treated, HIV-infected Adults

Trial Profile

A Phase I Study to Evaluate the Safety, Tolerability, and Effect of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), on Markers of HIV Persistence in ART-treated, HIV-infected Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs VRC 01 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Mar 2017 New trial record
    • 16 Feb 2017 Primary endpoint of cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells has not been met, according to results presented at the 24th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top